Letter | Published:

Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence

Nature volume 553, pages 351355 (18 January 2018) | Download Citation


The circadian clock imposes daily rhythms in cell proliferation, metabolism, inflammation and DNA damage response1,2. Perturbations of these processes are hallmarks of cancer3 and chronic circadian rhythm disruption predisposes individuals to tumour development1,4. This raises the hypothesis that pharmacological modulation of the circadian machinery may be an effective therapeutic strategy for combating cancer. REV-ERBs, the nuclear hormone receptors REV-ERBα (also known as NR1D1) and REV-ERBβ (also known as NR1D2), are essential components of the circadian clock5,6. Here we show that two agonists of REV-ERBs—SR9009 and SR9011—are specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and have no effect on the viability of normal cells or tissues. The anticancer activity of SR9009 and SR9011 affects a number of oncogenic drivers (such as HRAS, BRAF, PIK3CA and others) and persists in the absence of p53 and under hypoxic conditions. The regulation of autophagy and de novo lipogenesis by SR9009 and SR9011 has a critical role in evoking an apoptotic response in malignant cells. Notably, the selective anticancer properties of these REV-ERB agonists impair glioblastoma growth in vivo and improve survival without causing overt toxicity in mice. These results indicate that pharmacological modulation of circadian regulators is an effective antitumour strategy, identifying a class of anticancer agents with a wide therapeutic window. We propose that REV-ERB agonists are inhibitors of autophagy and de novo lipogenesis, with selective activity towards malignant and benign neoplasms.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    & The circadian clock: pacemaker and tumour suppressor. Nat. Rev. Cancer 3, 350–361 (2003)

  2. 2.

    , & Circadian control of the immune system. Nat. Rev. Immunol. 13, 190–198 (2013)

  3. 3.

    & Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)

  4. 4.

    et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 8, 1065–1066 (2007)

  5. 5.

    et al. Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature 485, 123–127 (2012)

  6. 6.

    et al. REV-ERBα and REV-ERBβ coordinately protect the circadian clock and normal metabolic function. Genes Dev. 26, 657–667 (2012)

  7. 7.

    & Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging 3, 479–493 (2011)

  8. 8.

    et al. Local circadian clock gates cell cycle progression of transient amplifying cells during regenerative hair cycling. Proc. Natl Acad. Sci. USA 110, E2106–E2115 (2013)

  9. 9.

    , , , & The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111, 41–50 (2002)

  10. 10.

    et al. Circadian clock control of the cellular response to DNA damage. FEBS Lett. 584, 2618–2625 (2010)

  11. 11.

    Circadian topology of metabolism. Nature 491, 348–356 (2012)

  12. 12.

    et al. The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110, 251–260 (2002)

  13. 13.

    et al. REV-ERBα, a heme sensor that coordinates metabolic and circadian pathways. Science 318, 1786–1789 (2007)

  14. 14.

    et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485, 62–68 (2012)

  15. 15.

    et al. REV-ERB-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat. Med. 19, 1039–1046 (2013)

  16. 16.

    et al. The clock gene Rev-erbα regulates pancreatic β-cell function: modulation by leptin and high-fat diet. Endocrinology 153, 592–601 (2012)

  17. 17.

    , & Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947 (2013)

  18. 18.

    et al. Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science 342, 1243417 (2013)

  19. 19.

    , , , & Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153–161 (2013)

  20. 20.

    Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401–410 (2012)

  21. 21.

    , & Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11, 709–730 (2012)

  22. 22.

    , & Temporal orchestration of circadian autophagy rhythm by C/EBPβ. EMBO J. 30, 4642–4651 (2011)

  23. 23.

    , , , & Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997)

  24. 24.

    & Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729–740 (2007)

  25. 25.

    et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16, 718–735 (2017)

  26. 26.

    et al. Oncogene-induced senescence results in marked metabolic and bioenergetic alterations. Cell Cycle 11, 1383–1392 (2012)

  27. 27.

    et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 23, 798–803 (2009)

  28. 28.

    et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005)

  29. 29.

    et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016)

  30. 30.

    et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013)

  31. 31.

    Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008)

  32. 32.

    et al. Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 15, 110–116 (2009)

  33. 33.

    et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat. Cell Biol. 13, 292–302 (2011)

  34. 34.

    et al. Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. Stem Cells 33, 2400–2415 (2015)

  35. 35.

    et al. Model-based analysis of ChIP–seq (MACS). Genome Biol. 9, R137 (2008)

  36. 36.

    et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature 498, 511–515 (2013)

  37. 37.

    & A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911–917 (1959)

  38. 38.

    et al. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 43, 14332–14339 (2004)

  39. 39.

    et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat. Med. 22, 1108–1119 (2016)

Download references


We thank K. V. Ly, L. Fijany, Y. Soda, M. Soda and M. Schmitt for technical assistance; F. d’Adda di Fagagna, S. Minucci, A. Viale, G. Gargiulo and J. Karlseder for discussion and feedback; the Narita, Gage, Burris, Amati and Shaw laboratories, and F. F. Lang for reagents; and the Salk Institute’s Waitt Advanced Biophotonics Center and Gene Targeting and Transfer, and M. Shokhirev and the Razavi Newman Integrative Genomics and Bioinformatics Core. G.S. is supported by the AIRC/Marie Curie International Fellowships in Cancer Research (12298), Istituto Superiore di Sanità, TRAIN ‘Training through Research Application Italian iNitiative’. M.V.P. is supported by the NIH (NIAMS grants R01-AR067273 and R01-AR069653) and a Pew Charitable Trust grant. X.W. is supported by a CIHR postdoctoral fellowship (MFE-123724). I.M.V is an American Cancer Society Professor of Molecular Biology. A.R. is supported by the NCI T32 grant, Salk Women in Science, Salk Excellerators Award and the Stavros Niarchos Foundation New Frontiers Salk Research Specialist Award. M.J.K. is supported by F30 DK112604. A.S. is supported by the NCI Cancer Center Support Grant P30 (CA014195 MASS core) and Dr. Frederick Paulsen Chair/Ferring Pharmaceuticals. This work was supported in part by a Worldwide Cancer Research grant and an American Federation of Aging Research mid-career grant M14322 to S.P. Additional support came from a Cancer Center Core Grant (P30 CA014195-38), the H. N. and Frances C. Berger Foundation, the Glenn Center for Aging Research and the Leona M. and Harry B. Helmsley Charitable Trust (grant #2012-PG-MED002).

Author information


  1. Regulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037, USA

    • Gabriele Sulli
    •  & Satchidananda Panda
  2. Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla, California 92037, USA

    • Amy Rommel
    •  & Inder M. Verma
  3. Department of Developmental and Cell Biology, University of California, Irvine, Irvine, California 92697, USA

    • Xiaojie Wang
    •  & Maksim V. Plikus
  4. Clayton Foundation Laboratories of Peptide Biology, Salk Institute for Biological Studies, La Jolla, California 92037, USA

    • Matthew J. Kolar
    •  & Alan Saghatelian
  5. Department of Genomic Medicine, The University of Texas MD, Anderson Cancer Center, Houston, Texas 77030, USA

    • Francesca Puca


  1. Search for Gabriele Sulli in:

  2. Search for Amy Rommel in:

  3. Search for Xiaojie Wang in:

  4. Search for Matthew J. Kolar in:

  5. Search for Francesca Puca in:

  6. Search for Alan Saghatelian in:

  7. Search for Maksim V. Plikus in:

  8. Search for Inder M. Verma in:

  9. Search for Satchidananda Panda in:


X.W. and M.V.P. performed experiments related to naevi. A.R. participated in xenograft experiments. F.P. performed experiments in Extended Data Figs 8g–l, 10h–j. M.J.K. performed lipidomic assays. G.S. designed the study, performed experiments, analysed data and wrote the manuscript. A.S, I.M.V. and M.V.P. supervised experiments and edited the manuscript. S.P. supervised, designed the study and reviewed the data and manuscript. All authors discussed the results and commented on the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Gabriele Sulli or Satchidananda Panda.

Reviewer Information Nature thanks S. Kay, L. Zender and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains the full scans of the immunoblots used in the figures.

  2. 2.

    Life Sciences Reporting Summary

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.